Cambridge-based Idera Pharmaceuticals Inc. reported its lead drug candidate, for moderate to severe plaque psoriasis, was more effective than a placebo in a Phase 2a clinical trial. Idera said 48 percent of patients with the condition (12 of 25) treated with IMO-3100 demonstrated improvement. The trial involved two dose levels of the drug administered for four weeks, with a four-week follow-up. None of the 12 patients who got placebos showed significant improvement.
Idera surges on positive drug-test results
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week